Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

Addressing Current Questions and Controversies in the Management of Metastatic Breast CancerПодробнее

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer ResearchПодробнее

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer TreatmentПодробнее

Dr. Hurvitz on Therapeutics for HER2+ Metastatic Breast CancerПодробнее

Dr. Hurvitz on Novel Agents in HER2-Positive Breast CancerПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Dr. Hurvitz on Standards of Care in HER2+ Breast CancerПодробнее

Dr. Hurvitz on How to Navigate HER2-Targeted Therapy in Breast CancerПодробнее

Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast CancerПодробнее

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast CancerПодробнее

Dr. Hurvitz on Treatment Options for HER2-Positive Breast CancerПодробнее

Dr. Hurvitz on Unmet Needs in HER2+ Breast CancerПодробнее

Dr. Hurvitz on the Need for Additional Research With Trastuzumab Deruxtecan in HER2+ Breast CancerПодробнее

Dr. Hurvitz on neoMONARCH Trial for HR+ Breast CancerПодробнее

Dr. Hurvitz on Novel Emerging Agents in HER2+ Breast CancerПодробнее

Dr. Hurvitz on Importance of Biosimilars in HER2+ Breast CancerПодробнее

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast CancerПодробнее

Dr. Hurvitz on HER2-Targeted Therapies in Breast CancerПодробнее

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast CancerПодробнее

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast CancerПодробнее

Dr. Hurvitz Discusses De-Escalation in HER2+ Breast CancerПодробнее